Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX + leflunomide vs MTX + hydroxychloroquine + sulfasalazine in MTX-inadequate response rheumatoid arthritis
KCT0007097Phase 4Not yet recruiting
- Sponsor
- Hanlim Pharm
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methotrexate, leflunomide, hydroxychloroquine, 5-aminosalicylic acid + sulphasalazine in rheumatoid arthritis (RA), sponsored by Hanlim Pharm. Planned start May 2022; status: not yet recruiting.
02
Drugs
methotrexateleflunomidehydroxychloroquine5-aminosalicylic acid + sulphasalazine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on KCT0007097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007097.